Category - Developments

Developments

Perimeter CEO significantly adds to holdings

According to a press release issued by Perimeter Medical Imaging AI (TSXV:PINK; OTCQB:PYNKF), it closed the final tranche of a prospectus offering of units of the company, in which its CEO, Adrian Mendes, participated...

July 29, 2025

Developments

Cook Medical’s launch of new iMRI division may help pave the way for wider and faster adoption of innovative procedures, like Profound’s TULSA

Cook Medical, a large family-owned medical device company known for its focus on minimally invasive treatment options, has launched a new Interventional Magnetic Resonance Imaging (iMRI) division, marking a significant...

July 29, 2025

Developments

Cognito presents positive Spectris data at AAIC; highlights Firefly collaboration for biomarker discovery using BNA technology

Closely held Cognito Therapeutics has announced five new poster presentations at the Alzheimer’s Association International Conference (AAIC) 2025, supporting the clinical efficacy and neuroprotective mechanism of its...

July 29, 2025

Developments

VVT Med completes RTO of V.V.T. Med and Exiteam Acquisition

VVT Med (TSXV: DXI.H) (formerly DXI Capital) announced that it has completed its previously announced acquisition of all of the outstanding securities of V.V.T. Med (VVT) and Exiteam Acquisition (EAC), according to the...

July 23, 2025

Developments

USPTO grants Enveric second patent allowance for next-gen mescaline derivatives

Enveric Biosciences (NASDAQ: ENVB) announced that the U.S. Patent and Trademark Office (USPTO) has granted a second Notice of Allowance for novel compounds within its next-generation, non-hallucinogenic mescaline...

July 23, 2025

Developments

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol

Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the critical advancement of its proprietary resveratrol platform, JOTROL, compared to conventional resveratrol formulations, citing breakthrough bioavailability and...

July 23, 2025

Developments

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

Autolus Therapeutics (NASDAQ: AUTL) has announced that the European Commission (EC) has granted marketing authorization for AUCATZYL for the treatment of adult patients aged 26 and over with relapsed or refractory B...

July 21, 2025

Developments

USPTO grants Autonomix patent for smart torquer device

Autonomix Medical (NASDAQ: AMIX) has announced that the United States Patent and Trademark Office (USPTO) has issued a patent for its smart torquer device. The device is designed to enhance the manipulation of elongated...

July 21, 2025

Developments

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license

Cuprina Holdings (NASDAQ: CUPR) has announced the appointment of Dr. Ronald Sherman, a leading innovator in maggot debridement therapy (MDT), as medical and scientific director, effective September 2025—securing the...

July 21, 2025

Developments

Knight files NDS for CREXONT in Canada

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...

July 18, 2025

Category - Developments

Subscribe